Nevakar unveils ophthalmic subsidiary, Vyluma
Vyluma Inc. will focus on the development and commercialization of therapies to treat ophthalmic diseases, including paediatric myopia.
Focusing on 24-month data of the PALADIN study
Dr Michael A. Singer speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
Measuring visual fields with cloud-based AI platform
Dr Mohamed Abou Shousha and Dr Richard Parrish II discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.
Linking patient imaging to AAO IRIS Registry clinical data
Dr. Michael Mbagwu speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.
Looking at real-world trial data replication outcomes of AAO IRIS Registry data
Dr Theodore Leng discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.
Clinical results analyze dexamethasone implant effect on macular thickness
Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Targeting neurodegenerative diseases using risuteganib
Dr Glenn J. Jaffe discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.
Study: Identifying link between endophthalmitis, coronavirus
A cluster of COVID-19 positive patients developed endophthalmitis, and investigators are searching for a link.
Analysis of an investigational ophthalmic solution for treating presbyopia-related symptoms
Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Evaluating long-term safety for micro-bypass implant + phaco in PXG
Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.
Controlling postop pain, inflammation in cataract patients: drug delivery vs drops
John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.
2 Clarke Drive Cranbury, NJ 08512